<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

    April 3, 2017

    VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).

    Biodesix Adds Biognosys’ Proteomics Technology To Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification Within Proteomic Signatures

    July 29, 2015

    Biodesix recently added Biognosys' Proteomics to their capabiltites.

    Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer

    March 11, 2015

    Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.

    Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC

    March 24, 2015

    The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.

    New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

    March 22, 2017

    A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.

    Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)

    November 6, 2015

    Biodesix data on proteomic and genomic blood-based assays presented at EORTC

    Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

    January 9, 2017

    Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.

    Aetna Provides Coverage for Biodesix’ VeriStrat Test

    June 8, 2015

    Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.

    Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

    February 2, 2017

    Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.

    Biodesix® and Progenetics Announce Distribution Agreement for Israel

    March 9, 2017

    Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
    1 2 3 4 5 6